Navigation Links
A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections
Date:12/15/2009

MALVERN, Pa. and WALTHAM, Mass., Dec. 15 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections. A drug's activity against MRSA is among the top factors that influences European physician drug selection for treating skin and skin structure infections. Other key factors that drive prescribing include an agent's skin penetration, its spectrum of activity and recommended use by national and hospital guidelines.

The new report entitled Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections (Europe) also finds that novel antibiotics in late-stage development may become useful therapeutic options for European physicians given their concern over MRSA. Two new injectable cephalosporins, Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca/Takeda's ceftaroline, offer broad-spectrum activity against MRSA and may provide convenient monotherapy options for physicians requiring broad-spectrum activity against gram-positive and gram-negative pathogens. Surveyed European specialists express willingness to use these agents in empiric therapy for complicated skin and skin structure infections, particularly in patients with suspected MRSA infections.

"Specialists we surveyed in Europe told us that they anticipate shifts in prescribing that will impact the skin structure infection market in the near future. In particular, physicians believe they will increase their empiric coverage of MRSA in complicated skin and skin structure infections," stated Decision Resources Analyst Lisa Arias. "MRSA infections are a great concern in the hospital setting and are a growing concern in the community setting because of their association with poorer outcomes and higher healthcare costs compared with non-resistant infections."

About the Report

AMR and Decision Resources' Hospital Anti-Infectives Insight Series: Skin and Skin Structure Infections (Europe) analyzes hospital antibiotic prescribing patterns in Europe using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. This report contains European data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:



    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


SOURCE Decision Resources; Arlington Medical Resources


'/>"/>
SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline
2. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
3. U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS
4. Reportlinker Adds Global Markets for Asthma and COPD Drugs
5. drugstore.com, inc. Has Best Day Ever on Cyber Monday
6. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
7. Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia
8. California American Water Celebrates No Drugs Down the Drain Week in San Diego
9. Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs
10. Reportlinker Adds Chinese Markets for Respiratory Drugs
11. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... 23, 2017 The key factors driving ... diabetic population, accelerating economic growth and increasing healthcare expenditure. Some ... higher life expectancy of ESRD patients, rising demand for home ... the expansion of the market is hindered by high treatment ... ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... Digital Scientists, a software innovation lab specializing in web design and ... Carolina location. The lab has set up shop at the renowned NEXT Innovation ... Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ CEO, ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):